Dr. Reddy's Laboratories Ltd. has launched the first generic version of Sugammadex Injection in the United States, marking its entry into the generic market for Merck Sharp & Dohme B.V.'s Bridion. The Hyderabad-based pharmaceutical company introduced the single-dose vials on the first day of generic availability, aiming to expand its hospital portfolio and improve patient access to affordable medicines. The branded reference product reported approximately $1.6 billion in U.S. sales for the latest 12-month period ended May 2026, according to IQVIA National Sales Perspectives data.

The launch includes two strengths of Sugammadex Injection: 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL). These formulations are indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. By securing first-to-market status, Dr. Reddy's underscores its execution capabilities and supply reliability in the competitive U.S. generics landscape.

Product Details

The Sugammadex Injection is manufactured through Dr. Reddy's global supply network, leveraging vertically integrated processes to ensure quality and consistency. The product serves as a direct generic equivalent to Bridion, which remains a registered trademark of Merck Sharp & Dohme B.V. The key product specifications are outlined below:

Market Context

Bridion holds a substantial presence in the U.S. hospital market, with sales reaching approximately $1.6 billion over the trailing twelve months ending May 2026. The introduction of the first generic alternative by Dr. Reddy's is expected to increase competition and potentially lower costs for healthcare providers. This launch aligns with Dr. Reddy's broader strategy to strengthen its footprint in key therapeutic areas, including pain management and anesthesia support, within its major markets such as the United States.

Strategic Significance

The timing of the launch on the very first day of generic availability highlights Dr. Reddy's preparedness and regulatory agility. In the generics sector, early entry often correlates with higher initial market share capture before subsequent competitors arrive. With the branded product generating $1.6 billion in recent sales, even a modest penetration rate represents a material revenue opportunity for Dr. Reddy's U.S. hospital business. This launch reinforces the company's focus on high-value specialty generics, potentially supporting margin stability in its North American operations.

Dr. Reddy's Laboratories has secured approval from the U.S. Food and Drug Administration (FDA) for its Rituximab biosimilar, marking a notable regulatory achievement for the pharmaceutical company. The approval adds to the company's expanding global biosimilars collection and underscores its continued focus on the biologics segment.

Exclusive U.S. Commercialization Partnership

As part of the commercial rollout strategy for the approved biosimilar, Fresenius Kabi has been designated as the exclusive partner responsible for selling the Rituximab biosimilar in the United States. This arrangement positions Fresenius Kabi as the sole U.S. distribution channel for the product following the regulatory clearance.

Strengthening the Global Biosimilars Portfolio

The U.S. FDA green light for the Rituximab biosimilar represents a meaningful addition to Dr. Reddy's global biosimilars lineup. The approval reflects the company's ongoing efforts to broaden its presence in the biosimilars market, a segment that has seen increasing regulatory and commercial activity across major markets including the United States.

*Source: *